![David J. Valacer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
David J.
Valacer worked as the Chief Medical Officer at Molecular Templates, Inc. and as a Principal at Weill Cornell Medical College.
He also briefly returned to Molecular Templates, Inc. as Chief Medical Officer in 2017.
Valacer holds a graduate degree from New York University and a doctorate from the University of Vermont College of Medicine.
Precedenti posizioni note di David J. Valacer
Società | Posizione | Fine |
---|---|---|
MOLECULAR TEMPLATES, INC. | Direttore Tecnico/Scientifico/R&S | 20/10/2017 |
Weill Cornell Medical College | Corporate Officer/Principal | - |
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di David J. Valacer
New York University | Graduate Degree |
University of Vermont College of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Aziende private | 1 |
---|---|
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
- Borsa valori
- Insiders
- David J. Valacer